"WALL STREET CORNER"
BY WALLSTREETCORNER.COM, INC.
www.WallStreetCorner.com
GeneLink, Inc.
GeneLink – Creator of the Dermagenetics™ Field
GeneLink’s Nutragenetics Profile™ & Dermagenetics™ DNA profile
assessments are powerful new tests. They are designed to help companies create &
deliver health, beauty, & wellness products & regimens that are ultimately more
effective -- because they can scientifically target an individual’s specific needs.
GeneLink is an attractive growth situation with substantial appreciation
potential. It is emerging from its R&D & startup phases, & is beginning to
establish licensing arrangements with major corporations that should propel it, in
our opinion, into a very profitable operation.
__________________________________________________________
Essentials
Business:
Symbol:
Shares Out (on 11/05/2003):
Approximate Float:
Market Cap (close 11/7/2003):
52-Week Range:
DNA Tests to Facilitate Genetically Guided Health, Beauty, &
Wellness
OTC BB: GNLK
27,716,319
12 million shares
$15.09 million*
$$0.20 - $0.80
* Using the number of shares at 11/05/03
_______________________________________________________________________________________________
Summary
GeneLink, Inc., since 1994, developed the world's first family centered DNA Bank & Hereditary Genetic
Information Service. With recent breakthroughs the company is a pioneer & leading provider of DNA tests created to
facilitate “genetically guided” health, beauty, & wellness products. The company both markets & licenses its
proprietary tests to the $1.4 trillion cosmetics, nutritional supplement, & healthcare industries.
GeneLink’s Nutragenetic Profile™ & Dermagenetics™ Profile
By analyzing an individual’s DNA, which can be taken from the mouth with a cotton swab, GeneLink provides
companies the ability to offer their consumer customers the benefit of personalized skincare, cosmetics, nutritional
supplements, or health & wellness regimens.
The Nutragenetic Profile™ examines important genes related to increased risks for oxidative stress, circulatory &
heart health, bone health, immune function, & the ability to combat environmental toxins.
The Dermagenetics™ profile examines important genes related to increased risks for certain skin conditions, skin
irritations, premature wrinkling, oxidative damage, environmental stresses & photo-aging.
GeneLink’s Patented DNA Collection System™
GeneLink has the only patented, FDA reviewed, non-invasive, self-administered DNA collection system available
today. The process is as easy to use as brushing one’s teeth! No invasive procedures are required & it takes just a few
minutes. A person simply swabs the inside of their mouth (inner cheek) & mails the swabs back to GeneLink’s
laboratories in the special envelopes. Everything along with easy-to-follow instructions is included. All materials &
forms are bar coded with a unique ID number to insure privacy & confidentiality.
Market Potential - Genomics & “The Wellness Revolution”
Genomics is currently a $1 billion industry & is projected to be a 10 billion dollar industry by the end of 2003.
Several billions of dollars have been spent on the human genome project so far, & millions more will be spent trying
to understand what all of this genomic information means. Genomics, as a segment of the healthcare industry, is a
multi-billion dollar industry worldwide & the market for personalized medicine & personalized health through
nutrition & skin care is expected to exceed $25 billion dollars by 2010.
Approximately one seventh of the U.S economy today, about $1.4 trillion, is devoted to the healthcare business.
By the year 2010, that number is expected to explode to nearly $3 trillion.
The following excerpt describes Genelink’s technology as well as market potential. (from “The Next Trillion,” by
best-selling author & economist Paul Zane Pilzer, pgs. 29-30). One of the central themes is the ‘The Wellness
Revolution’ currently taking place in the U.S. & the part genetics will play.
“Our demand for wellness based products & services is primarily driven by one function of the genetic code which
causes aging – from wrinkles that appear on our skin to the ultimate breakdown of our bodily organs. Over the long
term, the understanding & eventual manipulation of this genetic code holds the greatest promise for the wellness
industry.”
“By examining a person’s DNA, which can be taken from the mouth with just a small swab or scraping device, it is
already possible to predict the probability that a person will develop certain diseases, & soon, based on the recently
completed mapping of the human genome, it should be possible to predict every forthcoming disease or condition not
caused by external (i.e. diet & exercise) factors.
“Scientists expect this type of genetic testing to become widespread by 2010. In just the next few years, by using
this information to predict the probability to develop a certain condition, a wellness distributor could suggest a
vitamin- or supplement-based therapy.
“For example, a person with a genetic propensity to develop osteoporosis would be directed to take calcium
supplements, or a person with a genetic propensity for developing prostrate problems would be an early candidate to
take saw palmetto.”
Marketing Strategy
New products are ready & GeneLink has completed & is continuing to create marketing, licensing, & distribution
agreements with some of the worlds’ largest distributors of nutritional, skin-care, personal care, wellness, & anti-aging
products.
Mission
GeneLink’s clear mission is to utilize the latest genetic research information & applied technologies to provide
products & services that can assist in improving the quality of life.
Brief Scientific Review
GeneLink’s profiles examine genes in selected areas of physiologic & skin health. The Nutragenetic Profile™
measures increased risks for oxidative stress, circulatory & heart health, bone health, immune function, & the ability
to combat environmental toxins. Its Dermagenetics™ profile measures increased risks for certain skin conditions,
skin irritations, premature wrinkling, oxidative damage, environmental stresses, & photo-aging.
GeneLink’s profile assessments enable health care professionals, & nutritional & skin care companies to
recommend a specific & targeted regime of nutritional supplements, skin-care formulations, & wellness regimens that
have been specifically designed to compensate for certain predicted deficiencies. They are a powerful assessment tool
to help guide & optimize nutritional & skin care needs to provide individuals the best of health & appearance.
The profiles examine genes for the existence of single nucleotide polymorphisms (SNPs). These SNPs exist as
naturally occurring variations in genes in the human population. Many genes exhibit just a single nucleotide
difference that can result in a single amino acid substitution in the protein encoded by that gene. The specific SNPs
chosen are related to relative increases & decreases in biochemical activities of the genes & their product proteins. &
occur at relatively high frequencies in the population. All of these genes are well characterized in the scientific
literature.
GeneLink’s genetic profiles identify genetic variations that can impact important physiologic systems related to
long-term health maintenance. Genetic profiling information based on SNPs analyses can be used to design
appropriate antioxidant vitamin, nutrient, & skin-care formulations & offer a scientific personalized approach to
cosmetic, nutritional supplement selection, & wellness regimens.
Management
John R. DePhillipo is chairman, CEO, & founder. He was chairman & CEO of Applied Safety, Inc. Since 1994,
he has been responsible for developing the initial GeneLink “DNA banking concept” & establishing GeneLink’s DNA
laboratory & storage facility at the University of North Texas Health Science Center in Forth Worth. This resulted in
a long-term contract between GeneLink™ & the University. He also began to broaden GeneLink’s business model by
aggressively seeking new genomic technology patents which included GeneLink’s DNA Collection Kit®. In the late
1990’s he began pioneering the development of GeneLink’s breakthrough genetic profiling technologies (patents
pending) for worldwide licensing. His aggressive leadership style & marketing savvy has helped GeneLink earn
national & international recognition as a trusted resource for confidential DNA banking & has positioned GeneLink as
a leading provider of genomic technologies.
Robert P. Ricciardi, Ph.D. is treasurer & founder. He is a professor of microbiology at the University of
Pennsylvania, where he is chairman of the Microbiology & Virology Program of the Molecular Biology Graduate
Group. He received his Ph.D. from the University of Illinois at Urbana in cellular biology. He was a postdoctoral
fellow at Brandeis University & Harvard Medical School in the Department of Biological Chemistry, & was awarded
fellowships by the American Cancer Society, National Institutes of Health, & Charles A. King Trust. He developed
one of the first techniques in molecular biology, which has been widely used both to map genes & determine the
proteins they encode. While most of his research has centered on basic mechanisms of cancer, he developed,
patented, & has a patent pending for recombinant delivery vectors for use as vaccines & for potential use in gene
therapy. He served as a consultant to The National Department of Infectious Disease, has authored 55 publications,
has been awarded a NATO Visiting Professorship at Ferrara Medical School, Italy, & has been an invitational speaker
at various scientific meetings & a seminar guest speaker at the Mayo Clinic & Johns Hopkins University.
Monte Taylor is director of business development, marketing, & sales. As a management & enterprise consultant
for over 20 years, he specialized in strategic marketing plans, business development, & marketing communications for
mid-size & Fortune 500 companies. He has his MBA in marketing & management from Crummer Graduate School of
Business. He is focusing on rolling out GeneLink’s proprietary genetic profiling assessments to the direct selling,
nutrition, & skin-care industries worldwide.
Harold H. Harrison, M.D., Ph.D., FCAP is medical director & chief compliance officer. He served as corporate
medical director of genetic services for Quest Diagnostics & as overall medical director for the biochemical,
molecular, cytogenetic, & HLA laboratories of Genetrix, Inc., a national genetic services company (acquired by
Genzyme Genetics). He is a clinical pathologist with subspecialty training in all areas of genetic services, & a Ph.D.
in biochemical genetics. He is a Fellow of the College of American Pathologists & a member of the American
College of Medical Genetics & American Society of Human Genetics. He holds medical licenses in six states (AZ,
CA, IL, NJ, NV, & NY), & laboratory director’s licensure in NJ & NY. A former faculty member at the Univ. of
Chicago Pritzker School of Medicine, he has 80 publications & abstracts, & several OMIM/GDB citations for his &
collaborators’ genetic discoveries. He now holds a clinical faculty appointment with the Univ. of Arizona Medical
School.
Scientific & Medical Advisory Board
Robert P. Ricciardi, Ph.D.
Harold H. Harrison, M.D., Ph.D., FCAP
James W. Simkins, Ph.D. has his B.S. & M.S. from the University of Toledo & his Ph.D. Degree in physiology
from Michigan State University. At the University of Florida, College of Pharmacy, he was professor of
pharmacodynamics. He was chairman of the departments of pharmacodynamics & pharmaceutics, associate dean for
Research & Graduate Studies, director, Center for the Neurobiology of Aging, & the Frank Duckworth Professor of
Drug Discovery at the University of Florida. He has more than 230 peer-reviewed publications, a dozen patents for
his discoveries, & has edited two texts on Alzheimer’s disease therapy. He also served as the director of the
University of Florida Drug Discovery Group for Alzheimer’s disease (has sustained funding by the National
Institute on Aging to support research in the pharmacotherapy for Alzheimer’s disease). He was appointed to the
Medical & Scientific Advisory Council of the National Alzheimer’s Association, & became the chair of the
Department of Pharmacology & Neuroscience & director, Institute for Aging & Alzheimer’s Disease Research at the
University of North Texas Health Science at Fort Worth.
Robert J. Schwarzberg, M.D., F.A.C.C. is a board certified cardiologist & fellow of the American College of
Cardiology. His medical degree is from Wayne State University & his B.A. is from Columbia University. As
chairman & medical director of Cardiolife, a national cardiac monitoring company, he was instrumental in its business
& technology development from a startup to $18M revenue with substantial intellectual property including a patent on
a hybrid smart event recorder. He is chief medical officer of Ralin Medical & its subsidiaries – Cardiac
Solutions (now CorSolutions) & LifeWatch. He is CMO of LifeWatch, the largest arrhythmia management company
in the U.S.
Arthur J. Eisenburg, Ph.D. is director, DNA Identity Lab, & associate professor of pathology, University
of North Texas Health Science Center, & heads its DNA laboratories. He is chairman to the FBI's DNA advisory
board, & is one of the only two Americans on a 10-member international commission formed to standardize forensic
DNA testing in Europe. He was selected as a member of the prestigious DNA Advisory Board established by the U.S.
Congress. He also participates on the American Association of Blood Banks Parentage & 127; Testing Committee for
laboratory accreditation; helped establish a crime lab for the Texas Department of Public Safety as well as pediatric
bone marrow transplant diagnostic facility for a local hospital.
Henry T. Lynch, M.D., is professor & chairman, Department of Preventive Medicine, Creighton University
School of Medicine, director of the Creighton Cancer Center, & a member of the editorial boards of the Journal of
Tumor Marker Oncology, Anti-Cancer Research - International Journal of Cancer Research & Treatment, &
American Journal of Medical Genetics. He is the recipient of the American Cancer Society 1997 Medal of Honor,
Clinical Research Award, & the Association of Community Cancer Center's 1996 Outstanding Advancement in
Clinical Research Award.
Financial Status*
Current Assets:
Total Assets:
Current Liabilities:
Total Liabilities:
Accumulated Deficit:
Shareholders Deficit:
$207,388
$397,179
$390,107
$747,452
($7,361,213)
($350,273)
Revenue (Year to 09/30/2003):
Net Loss (Year to 09/30/2003):
$64,753
$1,172,554
* At 09/30/2003 – GeneLink is just emerging from its R&D as well as its lengthy start-up phase. Its
balance sheet & P&L should be substantially improved as the companies with which
it is working begin selling those products that rely on GeneLink’s technology.
Advantages
We like the significant progress GeneLink has made. We particularly like the fact that GeneLink’s patents pending
profile assessments are the basis for such remarkable marketing capability, & that John DePhillipo is establishing
relationships with major players in the key industries that can best utilize GeneLink’s technology.
We suggest that you seriously look into this emerging situation. In our opinion, it has exceptional long-term appreciation
potential. We feel it’s somewhat like Intel, Microsoft, Xerox, or IBM probably was when they were at the same age as
GeneLink. We like to have participants at WallStreetCorner that have this kind of potential. Is there risk? Of course – there
is always high risk when the appreciation potential is so high. We therefore believe that GeneLink is suitable for those
investors who can tolerate high risk to enjoy the possibility of very substantial growth.
Contact
Call Maria DePhillipo at 609-823-6991, Email genelink@aol.com, or write P.O. Box 3212, Margate, NJ 08402
www.genelink.info
Dislaimer: The public companies covered in the "Special Situation" section of www.WallStreetCorner.com & in the
"Emerging Growth Opportunities By Industry" section of www.Small-CapTrader.com normally pay an Annual Base Fee
of US$7,500 cash for such coverage. In the case of GNLK, we have received 30,000 restricted shares. Information
displayed by WallStreetCorner or Small-Cap Trader does not constitute an offer to buy, sell, or trade a security of any
kind, including stock. Neither Larry Oakley, & /or WallStreetCorner, & /or Small-Cap Trader recommend that any
person, institution, or other entity make any decisions or form any opinions, etc. based on the information on these sites.
All visitors to these sites are urged to consult a qualified financial professional before taking any actions in regards to
buying, selling, or trading securities (stocks or other forms of equity). Companies covered in Conservative Speculator, a
newsletter accessed from WallStreetCorner, or in any of Larry Oakley's other editorial venues do not pay for such
editorial coverage; the companies Larry covers editorially have never, do not now, & never will be charged for editorial
coverage. The companies that pay the $7,500 Annual Base Fee or any portion thereof are told this verbally, & their Web
Participation Contract contains the following clause: "It is understood that editorial coverage by Lawrence C. Oakley in
Conservative Speculator; his Opinion, Stock Pick, Comment, Small-Cap Pick, & other columns; contributions to
national media; radio/TV interviews; or speaking engagements has always been, is now, & will always be without cost,
& that his editorial coverage is not a part of this contract."
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this document
looking forward in time involve risks & uncertainties, & therefore actual results may be materially different. Factors that
could cause actual results to differ include activity levels in the securities markets & other risk factors such as customer
order rates, cancellations, late delivery of customer components, late system delivery, production delays, dependence
upon certain customers, dependencies upon key executives, competition, product liability risk, control by management, &
other risks detailed in the applicable U.S. Securities & Exchange Commission requirements.